Pharmacology/Pharmaceutical Industry
NICE Guideline | Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults.
25 Apr, 2022 | 01:11h | UTC
Anticholinergic medications and dementia: should we be worried?
25 Apr, 2022 | 00:14h | UTCCommonly-prescribed drugs and dementia: should we be worried? – Evidently Cochrane
Original Review:
Related:
How well do you know your anticholinergic (antimuscarinic) drugs? – Therapeutics Initiative
Anticholinergic drugs and risk of dementia: case-control study – The BMJ
Commentary on Twitter
Commonly-prescribed drugs & dementia: should we be worried? https://t.co/pvWxT6q48Z A @CochraneUK blog: Jodi Watt (a researcher @UofGlasgow) explores the @CochraneDCIG evidence on whether #anticholinergics might increase people’s risk of future memory problems, or even #dementia
— The Cochrane Library (@CochraneLibrary) April 22, 2022
Perspective: Delivering precision oncology to patients with cancer.
25 Apr, 2022 | 00:13h | UTCDelivering precision oncology to patients with cancer – Nature Medicine (free for a limited period)
Commentary on Twitter
A Perspective in @NatureMedicine outlines the major challenges to the implementation of precision oncology and discusses critical steps toward resolving them. https://t.co/7l3WmFffn3 pic.twitter.com/oxFMZGZunf
— Nature Portfolio (@NaturePortfolio) April 24, 2022
WHO recommends highly successful COVID-19 therapy (nirmatrelvir-ritonavir) and calls for wide geographical distribution and transparency from originator.
22 Apr, 2022 | 09:36h | UTCSee also:
A living WHO guideline on drugs for covid-19 – The BMJ
Therapeutics and COVID-19: living guideline – World Health Organization
Related:
Commentary on Twitter
🔥 Our latest @WHO living guidance on drugs for #COVID19, with new recommendations for nirmatrelvir-ritonavir & updated recommendation for remdesivir in non-severe illness.@bmj_latest: https://t.co/KuJjwzeTPV@WHO: https://t.co/n3iQx3pdmY
@theMAGICapp: https://t.co/dA7YYzeAZ1 pic.twitter.com/LvAhJf70UY
— Arnav Agarwal (@ArnavAgarwalMD) April 21, 2022
UK drug regulator advises patients and doctors against the use of Pregabalin during pregnancy due to a possible increased risk of congenital malformations.
22 Apr, 2022 | 09:31h | UTCSee also: Pregabalin and risks in pregnancy – Medicines and Healthcare products Regulatory Agency
Source: Avoid prescribing pregabalin during pregnancy if possible, says UK drug regulator – The BMJ ($)
Commentary on Twitter
The Medicines and Healthcare Products Regulatory Agency (@MHRAgovuk) has strengthened its warning about avoiding pregabalin during pregnancy after new data showed an increased risk of major congenital malformations associated with the drug https://t.co/ghGvqCqA0C
— The BMJ (@bmj_latest) April 22, 2022
RCT: Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for prevention of Covid-19.
21 Apr, 2022 | 10:29h | UTC
Commentary on Twitter
AZD7442 (tixagevimab/cilgavimab) found to have about 76% efficacy in preventing symptomatic Covid-19 infection. https://t.co/8tmvz3xI4I pic.twitter.com/fOegZjBRA6
— NEJM (@NEJM) April 20, 2022
[News release – not published yet] New guidelines from WHO recommend a simpler, safer treatment for cryptococcal disease in people living with HIV.
21 Apr, 2022 | 10:28h | UTCRelated Study: Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis – New England Journal of Medicine (link to abstract – $ for full-text)
SARS-CoV-2 vaccination and myocarditis in a Nordic cohort study of 23 million residents.
21 Apr, 2022 | 10:23h | UTCEditorial: Communicating the Benefits of Vaccination in Light of Potential Risks
USPSTF Draft Statement: Postmenopausal women should not use hormone therapy to prevent chronic health problems.
20 Apr, 2022 | 10:15h | UTCDraft Recommendation Statement: Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons – U.S. Preventive Services Task Force
Commentary: USPSTF Advises Against Hormone Therapy to Prevent Chronic Conditions – HealthDay
Studies highlight meningitis vaccine’s potential against gonorrhea.
20 Apr, 2022 | 10:06h | UTCCommentary: Studies highlight meningitis vaccine’s potential against gonorrhea – CIDRAP
News Release: Threat of untreatable gonorrhoea could be tackled using an existing meningitis vaccine – The Lancet
Study 1: Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study – The Lancet Infectious Diseases (link to abstract – $ for full-text)
Study 2: Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study – The Lancet Infectious Diseases (link to abstract – $ for full-text)
An observational study suggests coprescription of Phosphodiesterase Type 5 Inhibitors (i.e., sildenafil) and oral Nitrates is not associated with increased risk of adverse cardiovascular outcomes in male patients with ischemic heart disease.
20 Apr, 2022 | 10:11h | UTCCommentaries:
PDE5 Inhibitors Prescribed for Men on Oral Nitrates for IHD – HealthDay
M-A: Association of immune checkpoint inhibitors with neurologic adverse events.
20 Apr, 2022 | 09:34h | UTCInvited Commentary: Neurological Toxic Effects Associated With Treatment With Immune Checkpoint Inhibitors—Are We Really Safer Now? – JAMA Network Open
Related:
Autoimmune Encephalitis Related to Cancer Treatment With Immune Checkpoint Inhibitors: Systematic Review – Neurology (link to abstract – $ for full-text)
Commentary on Twitter
Meta-analysis of 39 RCTs found immune checkpoint inhibitors have lower risk of neurological adverse effects compared to cytotoxic chemotherapy, but higher than placebo, across a range of malignancies. https://t.co/02GhICcu5H
— JAMA Network Open (@JAMANetworkOpen) April 19, 2022
Omicron-specific Sinopharm, Sinovac COVID vaccine candidates cleared for clinical trial.
19 Apr, 2022 | 02:25h | UTCOmicron-specific Sinopharm, Sinovac COVID vaccine candidates cleared for clinical trial – Reuters
Commentary on Twitter
In China, #Omicron-specific vaccines are slated for clinical trials. The vaccine candidates were developed by a Sinopharm subsidiary and Sinovac Biotech. The vaccines are headed to clinical trials in Hong Kong https://t.co/6Y9LsGCKbn
— delthia ricks 🔬 (@DelthiaRicks) April 17, 2022
A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease.
19 Apr, 2022 | 02:14h | UTC
Commentary on Twitter
🆕💥💥Systematic Review collected efficacy & effectiveness values by vaccine platform, disease outcome, number of doses, & SARS-CoV-2 variants
The spread of the Omicron beginning late 2021 is at least partially driven by reductions in vaccine effectiveness https://t.co/A7hDTQGY4K— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) April 18, 2022
RCT: Allopurinol is noninferior to febuxostat for controlling gout flares.
19 Apr, 2022 | 02:05h | UTCComparative Effectiveness of Allopurinol and Febuxostat in Gout Management – NEJM Evidence (link to abstract – $ for full-text)
Cohort Study: Association of treatment with antipsychotics, antidepressants, or both with movement disorders and seizures among children and adolescents with depression.
19 Apr, 2022 | 01:50h | UTC
Commentary on Twitter
In this cohort study, adjunctive antipsychotics with antidepressants were associated with movement disorders and seizures compared with antidepressant monotherapy in children and adolescents with depression. https://t.co/3SVKEThwkR
— JAMA Network Open (@JAMANetworkOpen) April 15, 2022
Analysis of an intervention for emergency medical services personnel to reduce epinephrine dosing errors in infants.
19 Apr, 2022 | 01:52h | UTC
Commentary on Twitter
In this QI study, an infant resuscitation simulation intervention using 1mL syringes to draw up epinephrine (vs dosing from prefilled 10mL syringes) was associated with increased appropriate epinephrine use & fewer dosage errors, in less time. https://t.co/M3ztB1LMDi
— JAMA Network Open (@JAMANetworkOpen) April 15, 2022
Review: Paradoxical reactions to biologicals in chronic inflammatory systemic diseases.
19 Apr, 2022 | 01:48h | UTC
Review: The safety of antirheumatic drugs.
19 Apr, 2022 | 01:42h | UTCThe Safety of Antirheumatic Drugs – Deutsches Ärzteblatt International
Endocrine therapies for breast and prostate cancers: Essentials for primary care.
19 Apr, 2022 | 01:14h | UTC
M-A: Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination.
18 Apr, 2022 | 10:32h | UTCCommentaries:
Myopericarditis following COVID-19 vaccination is rare, finds international study – The Lancet
Study explores myopericarditis incidence and COVID-19 vaccination – News Medical
Commentary on Twitter
NEW—Myopericarditis following #COVID19 vaccination is rare, finds international study published in @LancetRespirMed: https://t.co/d3ZRvTWrGB pic.twitter.com/6sHiRyEbTk
— The Lancet (@TheLancet) April 11, 2022
Guidelines for therapeutic drug monitoring of vancomycin in the framework of model-informed precision dosing.
18 Apr, 2022 | 10:26h | UTCRelated Guideline:
Commentary on Twitter
https://twitter.com/IDPharmacometrx/status/1514219239732912131
A nationwide observational analysis in Israel showed a fourth dose of the Pfizer vaccine may reduce the short-term risk of Covid-19–related outcomes.
14 Apr, 2022 | 08:51h | UTCEditorial: Covid-19 Boosters — Where from Here?
Related:
COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines.
Perspective: The evidence on 4th doses of covid vaccines & the thorny question of age thresholds.
U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.
[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.
Covid-19: Fourth vaccine doses—who needs them and why?
[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.
Commentary on Twitter
In Israel, a fourth dose of BNT162b2 vaccine effective in reducing the short-term risk of Covid-19–related outcomes among those who had received a third dose at least 4 mos earlier. https://t.co/WtHiR9WbLW pic.twitter.com/yzWRLlgHUi
— NEJM (@NEJM) April 13, 2022
Covid-19: What is the evidence for the antiviral molnupiravir?
14 Apr, 2022 | 08:47h | UTCCovid-19: What is the evidence for the antiviral molnupiravir? – The BMJ
RCT: Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children.
14 Apr, 2022 | 08:43h | UTCEfficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)